Muscae volitantes — “eye floaters” are those little, transparent threads that you see floating across your eyeball. Generally ...

This drug has the potential to be more targeted than others currently being studied, and we hope it will result in fewer ...

The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and ...

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

Frontotemporal dementia can be hard to diagnose because while dementia can be part of the illness, it's not a factor in all ...

Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.

Outcomes may improve with disease-modifying drugs and lifestyle change if Alzheimer's could be identified earlier.

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Discover how exercise, a healthy diet, and socialization can help combat Alzheimer's disease. Learn more about the importance ...

A team of international researchers has found a promising new drug candidate for the treatment of Alzheimer’s disease. The scientists say they have developed a peptide inhibitor called RI-AG03 ...

Longview residents were out in front of the Gregg County Courthouse on Saturday to take part in the Walk to End Alzheimer’s ...

Researchers show that a pill form of the drug dronabinol, an FDA-approved synthetic version of marijuana's main ingredient, THC, reduces agitation in patients with Alzheimer's by an average of 30%.